Company profile: KisoJi Biotechnology
1.1 - Company Overview
Company description
- Provider of biotechnology solutions for healthcare and life sciences R&D, offering KisoMouse, a transgenic mouse platform for single-domain antibodies; KisoSeek, an NGS- and AI-guided structural antibody screening tool; KisoBody, a multi-functional, multi-specific antibody format; and therapeutic candidates including KJ-103 (TROP2, IND-enabling, solid tumors), KJ-101 (PD1/CD47/D2, IND-enabling), and KJ-102 (PD1/CD47/CD36, research, AML).
Products and services
- KisoBody: A custom-engineered, multi-functional and multi-specific antibody format that architects binding to multiple antigens or epitopes simultaneously for combined targeting
- KisoSeek: An AI-enabled structural antibody screening tool that uses next-generation sequencing to guide antibody selection
- KJ-101: An IND-enabling, tri-specific antibody targeting PD1, CD47, and D2 for solid tumors, enabling simultaneous engagement of three defined antigens
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to KisoJi Biotechnology
Medfusion Services
HQ: United States
Website
- Description: Provider of integrated clinical laboratory and clinical trial services, offering diagnostic testing (solid tumor, hematopathology, women's health, urology, general health), molecular diagnostics and test development, pathology services, and clinical trial support including specimen collection, processing, testing, and guidance for specimen packaging and shipping.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medfusion Services company profile →
Favrille
HQ: United States
Website
- Description: Provider of targeted immunotherapies, focused on research, development and commercialization for the treatment of cancer and other diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Favrille company profile →
TAE Life Sciences
HQ: United States
Website
- Description: Provider of biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT), offering the Alphabeam compact hospital-use tandem accelerator neutron source, BNCT combining boron-10 drugs and neutron beams to selectively destroy cancer cells, and TC220, a boronated amino acid analog targeting cancers including GBM, breast, and melanoma; the only company with comprehensive target drug and neutron technology product.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TAE Life Sciences company profile →
Everest Medicines
HQ: United States
Website
- Description: Provider of novel pharmaceutical therapies, including VELSIPITY (etrasimod), an oral once-daily S1P modulator for moderately to severely active ulcerative colitis; Nefecon, an oral delayed-release budesonide for primary IgA nephropathy in adults; Xerava (eravacycline), an IV antibiotic for complicated intra-abdominal infections; Zetomipzomib for autoimmune diseases; EVER001 for renal diseases; and an mRNA platform for vaccines and therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Everest Medicines company profile →
Fusion Pharmaceuticals
HQ: Canada
Website
- Description: Provider of clinical-stage radiopharmaceuticals and targeted alpha therapies for oncology, leveraging deep radiochemistry and Fast-Clear Linker Technology to improve safety. Pipeline includes FPI-2265 targeting PSMA in prostate cancer (Phase 2), FPI-1434 targeting IGF-1R, and FPI-2059 targeting NTSR1. Offers manufacturing expertise to build commercial supply chains.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fusion Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for KisoJi Biotechnology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to KisoJi Biotechnology
2.2 - Growth funds investing in similar companies to KisoJi Biotechnology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for KisoJi Biotechnology
4.2 - Public trading comparable groups for KisoJi Biotechnology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →